Literature DB >> 21918423

Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir.

Deborah Persaud1, Katherine Luzuriaga, Carrie Ziemniak, Petronella Muresan, Thomas Greenough, Terry Fenton, Amanda Blackford, Kimberly Ferguson, Natalie Neu, Coleen K Cunningham.   

Abstract

OBJECTIVES: Therapeutic HIV vaccinations may alter the size of the resting memory CD4 T-cell latent HIV reservoir as HIV establishes latency when memory responses are formed, including those toward HIV. Alternatively, latently infected CD4 T cells maybe killed, while exiting the reservoir upon activation.
METHODS: The effect of therapeutic immunization with modified vaccinia Ankara and Fowlpox-based HIV vaccines on the latent reservoir was examined in 19 young adults who were receiving effective antiretroviral therapy. Correlations between size of the reservoir [measured in infectious units per million (IUPM)] resting CD4 T cells and HIV-specific immune responses, including immune activation were examined. Decay of the reservoir was assessed using random-effects model.
RESULTS: A modest transient decrease in the size of the reservoir was observed at week 40 [mean -0.31 log(10) IUPM (95% confidence interval: -0.60 to -0.03; P = 0.03] following HIV vaccinations. The estimated half-life (T1/2) of the reservoir during the 40 weeks following vaccination was 9.8 months and statistically different from zero (P = 0.02), but 35.3 months and not different from zero (P = 0.21) over 72 weeks of study. Latent reservoir size at baseline was not correlated with HIV-specific CD4, CD8 responses or immune activation, but became correlated with CD4 IFNγ (r = 0.54, P = 0.02) and IL-2 responses at 6 weeks after immunization (r = 0.48, P = 0.04).
CONCLUSION: Therapeutic HIV vaccinations led to a transient increase in decay of latently infected CD4 T cells. Further studies of therapeutic HIV vaccines may provide important insights into facilitating decay of the latent reservoir. 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918423      PMCID: PMC3314338          DOI: 10.1097/QAD.0b013e32834cdaba

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

1.  Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.

Authors:  Laura Papagno; Galit Alter; Lambert Assoumou; Robert L Murphy; Felipe Garcia; Bonaventura Clotet; Martin Larsen; Martine Braibant; Anne-Geneviève Marcelin; Dominique Costagliola; Marcus Altfeld; Christine Katlama; Brigitte Autran
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

2.  The quest for an HIV-1 therapeutic vaccine.

Authors:  Rajesh Tim Gandhi; Marcus Altfeld
Journal:  J Infect Dis       Date:  2005-07-15       Impact factor: 5.226

3.  Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Authors:  Tae-Wook Chun; Danielle Murray; J Shawn Justement; Claire W Hallahan; Susan Moir; Colin Kovacs; Anthony S Fauci
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

4.  A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.

Authors:  Jonathan B Angel; Jean-Pierre Routy; Cecile Tremblay; Dieter Ayers; Ryan Woods; Joel Singer; Nicole Bernard; Colin Kovacs; Fiona Smaill; Sanjay Gurunathan; Rafick-Pierre Sekaly
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

5.  A therapeutic dendritic cell-based vaccine for HIV-1 infection.

Authors:  Felipe García; Núria Climent; Lambert Assoumou; Cristina Gil; Nuria González; José Alcamí; Agathe León; Joan Romeu; Judith Dalmau; Javier Martínez-Picado; Jeff Lifson; Brigitte Autran; Dominique Costagliola; Bonaventura Clotet; Josep M Gatell; Montserrat Plana; Teresa Gallart
Journal:  J Infect Dis       Date:  2011-01-13       Impact factor: 5.226

6.  Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.

Authors:  Matthew C Strain; Susan J Little; Eric S Daar; Diane V Havlir; Huldrych F Gunthard; Ruby Y Lam; Otto A Daly; Juin Nguyen; Caroline C Ignacio; Celsa A Spina; Douglas D Richman; Joseph K Wong
Journal:  J Infect Dis       Date:  2005-03-29       Impact factor: 5.226

7.  Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.

Authors:  Wei Lu; Luiz Claudio Arraes; Wylla Tatiana Ferreira; Jean-Marie Andrieu
Journal:  Nat Med       Date:  2004-11-28       Impact factor: 53.440

8.  Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.

Authors:  Jonathan Z Li; Zabrina L Brumme; Chanson J Brumme; Hongying Wang; John Spritzler; Michael N Robertson; Michael M Lederman; Mary Carrington; Bruce D Walker; Robert T Schooley; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

9.  HIV-specific CD4+ T cells may contribute to viral persistence in HIV controllers.

Authors:  Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Tzong-Hae Lee; Michael P Busch; Jeffrey N Martin; Joseph M McCune; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2011-01-18       Impact factor: 9.079

10.  Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P Moss; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; A Hurley; M Markowitz; D D Ho; A J McMichael; D F Nixon
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more
  19 in total

1.  Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Authors:  Wen Shi Lee; Anne B Kristensen; Thomas A Rasmussen; Martin Tolstrup; Lars Østergaard; Ole S Søgaard; Bruce D Wines; P Mark Hogarth; Arnold Reynaldi; Miles P Davenport; Sean Emery; Janaki Amin; David A Cooper; Virginia L Kan; Julie Fox; Henning Gruell; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

2.  Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Authors:  Zabrina L Brumme; Hanwei Sudderuddin; Carrie Ziemniak; Katherine Luzuriaga; Bradley R Jones; Jeffrey B Joy; Coleen K Cunningham; Thomas Greenough; Deborah Persaud
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

3.  HIV: Shock and kill.

Authors:  Steven G Deeks
Journal:  Nature       Date:  2012-07-25       Impact factor: 49.962

4.  Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Authors:  Jonathan Z Li; Andrea Heisey; Hayat Ahmed; Hongying Wang; Lu Zheng; Mary Carrington; Terri Wrin; Robert T Schooley; Michael M Lederman; Daniel R Kuritzkes
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

5.  HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.

Authors:  Cristina Andrés; Montserrat Plana; Alberto C Guardo; Carmen Alvarez-Fernández; Nuria Climent; Teresa Gallart; Agathe León; Bonaventura Clotet; Brigitte Autran; Nicolas Chomont; Josep M Gatell; Sonsoles Sánchez-Palomino; Felipe García
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

6.  The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression.

Authors:  Adit Dhummakupt; Lilly V Siems; Dolly Singh; Ya Hui Chen; Thuy Anderson; Aleisha Collinson-Streng; Hao Zhang; Purvish Patel; Allison Agwu; Deborah Persaud
Journal:  J Infect Dis       Date:  2019-01-01       Impact factor: 5.226

Review 7.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728

Review 8.  Prospects for treatment of latent HIV.

Authors:  K M Barton; B D Burch; N Soriano-Sarabia; D M Margolis
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875

Review 9.  Immune activation and HIV persistence: implications for curative approaches to HIV infection.

Authors:  Nichole R Klatt; Nicolas Chomont; Daniel C Douek; Steven G Deeks
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  Human immunodeficiency virus vaccine an update.

Authors:  Vt Beena; Kanaram Choudhary; R Rajeev; R Sivakumar; R Heera; Sk Padmakumar
Journal:  J Oral Maxillofac Pathol       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.